\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Joint Research CenterThe Joint Research Center (JRC), the European Commission’s science and knowledge service, has launched three new calls for the purposes of training and capacity building in its scientific laboratories and facilities to people working in academia and research organisations, small and medium enterprises (SMEs), and more in general to the public and private sector. More information on this initiative can be found here or in this JRC Brochure.
It concerns the following three calls:
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI, data & cloud Advanced Digital Skills Deployment: Best use of technologies
The first Digital Europe calls in the domains AI-continent, advanced digital skills and deployment & best use of digital technologies are now open for submission. Deadline to submit proposals for these calls is 2 September 2025. Please find here below an overview of all related call topics: AI-continent Apply AI: GenAI for the pu... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
